Loading...
Loading...
LSTA| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 48.0K |
| Gross Profit | -48.0K |
| Operating Expense | 6,844.0K |
| Operating I/L | -6,844.0K |
| Other Income/Expense | 657.0K |
| Interest Income | 0.0K |
| Pretax | -6,187.0K |
| Income Tax Expense | -1,327.0K |
| Net Income/Loss | -4,860.0K |
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of cellular therapies aimed at reversing disease and promoting tissue regeneration. The company's product candidates include HONEDRA, in Phase II clinical trial for critical limb ischemia; XOWNA, in Phase IIb clinical trial for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for pre-dialysis patients with chronic kidney disease. By advancing these innovative therapies through clinical trials and potential commercialization, Lisata Therapeutics generates revenue from the sale and licensing of its cellular therapy products.
